|
**Overview**: **OncoPro Hepatocellular Carcinoma Screening Assay****Introduction**: The OncoPro Hepatocellular Carcinoma Screening Assay Test is a diagnostic tool designed to screen for alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) in plasma samples, facilitating the diagnosis of liver cancer. Associated with hepatocellular carcinoma, this oncologic condition presents with jaundice, abdominal pain, and severe complications like metastasis if untreated, particularly in individuals with chronic hepatitis or cirrhosis. Per the 2023 American Association for the Study of Liver Diseases guidelines, the test employs molecular pathology with PCR technology, delivering detailed biomarker identification over 5-7 days with high sensitivity and specificity, making it a valuable tool for definitive diagnosis in molecular pathology settings. This diagnostic falls under cancer screening and targets individuals with hepatic symptoms, addressing the challenge of accurate biomarker classification to guide surgical resection or chemotherapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its plasma-based approach ensures non-invasive detection.**Other Names**: HCC Screening Test.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2010s by various molecular labs, this test advanced liver cancer diagnostics by standardizing multi-marker liquid biopsy analysis.**Purpose**: The test screens for alpha-fetoprotein and des-gamma-carboxy prothrombin to guide liver cancer diagnosis, assess oncologic status, and inform treatment and prevention strategies.**Test Parameters**: Presence of alpha-fetoprotein and des-gamma-carboxy prothrombin, detected with high specificity to indicate cancerous activity, typically observable in plasma at altered levels during active disease, with biomarker concentrations assessed to determine severity and distribution, providing a comprehensive profile of tumor damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected plasma components.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report jaundice, abdominal pain, or recent hepatic symptoms.**Specimen**: Plasma 2-4 mL, collected using EDTA tubes, transported within 8 hours to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling in a cool environment to preserve protein integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade proteins, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on jaundice, abdominal pain, prior liver issues, or family history of oncologic disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated cancer including metastasis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves plasma processing, protein extraction, PCR amplification, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 5-7 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 8 hours, improper storage conditions, cross-contamination with other samples, or recent therapy can affect results. Correlation with imaging or clinical evaluation is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible liver cancer, necessitating further investigation like ultrasound or oncology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.**Specialist Consultation**: Hepatologists or oncologists should be consulted for case management, treatment planning, and coordination with cancer programs.**Additional Supporting Tests**: Ultrasound, biopsy review, or AFP serum testing for confirmation.**Test Limitations**: The test may produce false negatives in early disease or false positives in inflammation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: AASLD Guidelines 2023, Journal of Hepatology 2024, Molecular Pathology 2025. |
